drugset / Trial / NCT03486301
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2018-02-15
- Primary completion
- 2024-03-31
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiquimod | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |